Background and aim
People living with type 2 diabetes and chronic kidney disease are at high risk for chronic kidney failure and cardiovascular disease.
Urine protein is an important sign of kidney damage and it is believed that lowering levels of urine protein may be related to protection of the kidneys over time.
Endothelin Receptor Antagonists and Sodium Glucose co Transporter 2 inhibitors (SGLT2i) have been shown to significantly reduce urine protein levels and delay progressive kidney function loss in patients with type 2 diabetes through distinct yet possibly synergistic mechanisms.
In this study, we look at how well the combination of two oral drugs called zibotentan, an Endothelin Receptor Antagonist, and dapagliflozin, an SGLT2 inhibitor, works for the treatment of chronic kidney disease in people with type 2 diabetes.
The main purpose of the study is to examine if the combination of zibotentan and dapagliflozin has beneficial effects on protein loss in the urine compared to zibotentan alone.
Randomized Double Blind Cross-Over Trial
start: Autumn 2022
end: Early 2024
University Medical Center Groningen